Last reviewed · How we verify
susceptibility test guided sequential therapy
A clinical strategy that uses antimicrobial susceptibility testing to guide sequential antibiotic therapy selection for optimal pathogen coverage.
A clinical strategy that uses antimicrobial susceptibility testing to guide sequential antibiotic therapy selection for optimal pathogen coverage. Used for Bacterial infections requiring sequential antibiotic therapy guided by susceptibility testing.
At a glance
| Generic name | susceptibility test guided sequential therapy |
|---|---|
| Sponsor | National Taiwan University Hospital |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
This is a therapeutic approach rather than a single drug entity. It involves performing susceptibility tests on isolated pathogens to determine which antibiotics are most effective, then sequentially administering antibiotics based on test results to maximize clinical efficacy and minimize resistance development. The strategy is particularly used in treating infections where empiric broad-spectrum therapy is initially given, then narrowed or adjusted based on culture and susceptibility data.
Approved indications
- Bacterial infections requiring sequential antibiotic therapy guided by susceptibility testing
Common side effects
Key clinical trials
- Susceptibility Testing Guided Versus Empirical Therapy for Refractory H. Pylori Infection (PHASE4)
- Efficacy of Vonoprazan-based Rescue Therapy for H. Pylori Eradication (NA)
- Susceptibility-Guided Sequential Therapy for Helicobacter Pylori Infection (NA)
- The Efficacy of the 7 Days Tailored Therapy as the 1st Eradication of H. Pylori Infection (NA)
- Genotypic Resistance Guided Versus Susceptibility Testing Guided Therapy for the First-line Eradication of H. Pylori (PHASE4)
- Genotypic Resistance Guided Therapy for Refractory H. Pylori Infection (PHASE4)
- The Efficacy of Susceptibility Test -Driven Sequential Therapy as the Third Line Therapy for Refractory Helicobacter Pylori Infection (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |